101 related articles for article (PubMed ID: 27405370)
21. Monitoring oxycodone use in patients with chronic pain: analysis of oxycodone and metabolite excretion in saliva and urine.
Moy KV; Ma JD; Morello CM; Atayee RS; Best BM
J Opioid Manag; 2014; 10(1):47-56. PubMed ID: 24604569
[TBL] [Abstract][Full Text] [Related]
22. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets.
Rubino M; Summers KH; Puenpatom A; Fu C; Ohsfeldt RL; Ben-Joseph RH
J Manag Care Pharm; 2011 Jun; 17(5):367-76. PubMed ID: 21657806
[TBL] [Abstract][Full Text] [Related]
23. Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry.
Neuvonen M; Neuvonen PJ
Ther Drug Monit; 2008 Jun; 30(3):333-40. PubMed ID: 18520605
[TBL] [Abstract][Full Text] [Related]
24. Authors' reply.
Elder NM; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Sep; 38(7):463. PubMed ID: 24986838
[No Abstract] [Full Text] [Related]
25. A Retrospective Analysis of Selected Opioids in Hair of Workplace Drug Testing Subjects.
Stowe GN; Paulsen RB; Hill VA; Schaffer MI
J Anal Toxicol; 2019 Aug; 43(7):553-563. PubMed ID: 31009051
[TBL] [Abstract][Full Text] [Related]
26. Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.
Edwards SR; Smith MT
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 848(2):264-70. PubMed ID: 17098487
[TBL] [Abstract][Full Text] [Related]
27. The Quantification of Oxycodone and Its Phase I and II Metabolites in Urine.
Truver MT; Jakobsson G; Chermà MD; Swortwood MJ; Gréen H; Kronstrand R
J Anal Toxicol; 2022 Feb; 46(1):55-63. PubMed ID: 33270113
[TBL] [Abstract][Full Text] [Related]
28. Excretion profile of hydrocodone, hydromorphone and norhydrocodone in urine following single dose administration of hydrocodone to healthy volunteers.
Valtier S; Bebarta VS
J Anal Toxicol; 2012 Sep; 36(7):507-14. PubMed ID: 22782534
[TBL] [Abstract][Full Text] [Related]
29. Oxycodone Concentrations and Metabolic Ratios in Femoral Blood from Fatal Intoxications and Other Causes of Death using LC-MS-MS.
Jakobsson G; Gréen H; Kronstrand R
J Anal Toxicol; 2021 Feb; 45(2):124-133. PubMed ID: 32435814
[TBL] [Abstract][Full Text] [Related]
30. Concentration of oxymorphone in postmortem fluids and tissue.
Garside D; Hargrove RL; Winecker RE
J Anal Toxicol; 2009 Apr; 33(3):121-8. PubMed ID: 19371460
[TBL] [Abstract][Full Text] [Related]
31. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.
Manchikanti L; Malla Y; Wargo BW; Fellows B
Pain Physician; 2011; 14(2):175-87. PubMed ID: 21412372
[TBL] [Abstract][Full Text] [Related]
32. LC-MS-MS Method for Analysis of Opiates in Wastewater During Football Games II.
Gul W; Stamper B; Godfrey M; Gul SW; ElSohly MA
J Anal Toxicol; 2016 Jun; 40(5):330-7. PubMed ID: 27052850
[TBL] [Abstract][Full Text] [Related]
33. Tentative identification of novel oxycodone metabolites in human urine.
Moore KA; Ramcharitar V; Levine B; Fowler D
J Anal Toxicol; 2003 Sep; 27(6):346-52. PubMed ID: 14516487
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
[TBL] [Abstract][Full Text] [Related]
35. The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone, oxymorphone and noroxycodone in Ringer solution, rat plasma and rat brain tissue.
Boström E; Jansson B; Hammarlund-Udenaes M; Simonsson US
Rapid Commun Mass Spectrom; 2004; 18(21):2565-76. PubMed ID: 15468158
[TBL] [Abstract][Full Text] [Related]
36. A sensitive LC-MS/MS method for the quantitation of oxycodone, noroxycodone, 6α-oxycodol, 6β-oxycodol, oxymorphone, and noroxymorphone in human blood.
Truver MT; Jakobsson G; Chermà MD; Swortwood MJ; Gréen H; Kronstrand R
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 May; 1171():122625. PubMed ID: 33744597
[TBL] [Abstract][Full Text] [Related]
37. Use of an algorithm applied to urine drug screening to assess adherence to an oxycontin regimen.
Couto JE; Webster L; Romney MC; Leider HL; Linden A
J Opioid Manag; 2009; 5(6):359-64. PubMed ID: 20073409
[TBL] [Abstract][Full Text] [Related]
38. Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone.
Schoedel KA; McMorn S; Chakraborty B; Zerbe K; Sellers EM
Pain Physician; 2010; 13(6):561-73. PubMed ID: 21102969
[TBL] [Abstract][Full Text] [Related]
39. Resolution of an apparent hook effect in Roche partner DRI oxycodone immunoassay.
Colón-Franco JM; Cox ET; Crosby DB; Dawling S
J Anal Toxicol; 2013; 37(6):376-81. PubMed ID: 23711948
[TBL] [Abstract][Full Text] [Related]
40. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.
Pöyhiä R; Seppälä T; Olkkola KT; Kalso E
Br J Clin Pharmacol; 1992 Jun; 33(6):617-21. PubMed ID: 1389934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
